Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002348 | A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma | PHASE2 | COMPLETED | - | — | — | - | - | Dec 19, 2020 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Mitoguazone | DRUG | - |
Inclusion Criteria Patients must have: * HIV positivity by ELISA confirmed by Western blot. * AIDS-related NHL that is refractory or relapsed. * Life expectancy of at least 12 weeks. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: * C...